NLS Global report

The exclusive global, ex-China, licensing agreement concerns the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

While reports of federal cutbacks across the US health, life sciences, and research landscapes continue to fuel anxiety among scientists, the situation may not be as dire as people fear, according to one investor.

On May 12, US President Trump signed an Executive Order to bring the prices Americans and taxpayers pay for prescription drugs in line with those paid by similar nations.

The policy prevents the NSF from awarding new research grants and from supplying allotted funds for existing grants, such as those that receive yearly increments of money.

Ahead of the EU Commission's presentation of a new strategy for life sciences, four industry organizations in Sweden, Lif – the research-based pharmaceutical companies, SwedenBIO, IKEM, and Swedish Medtech, have submitted a joint statement.

At a White House press event on Wednesday April 2, President Trump advanced the next stage of his economic plan by unveiling baseline tariffs of 10% on the vast majority of goods imported to the US. After several years of increasing export figures, Sweden’s pharmaceutical exports now risk being severely affected by the Trump administration’s tariffs, warns the industry association SwedenBIO.